(Reuters) – Merck has cleared a major anti-trust hurdle to its planned $17 billion (11 billion pound) acquisition of Sigma-Aldrich with the latter’s agreed sale of assets to Honeywell , the German drugmaker said on Tuesday.
Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.
“This is another key step towards completing the acquisition of Sigma-Aldrich,” Merck executive board member Bernd Reckmann said in a statement on Tuesday.
Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November.
The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction.
Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.
(Reporting by Georgina Prodhan; editing by Jason Neely)
Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.
Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.
Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless